| Assessment Status | Rapid Review Complete |
| HTA ID | 25002 |
| Drug | Sodium thiosulfate |
| Brand | Pedmarqsi® |
| Indication | Sodium thiosulfate (Pedmarqsi®) is indicated for the prevention of ototoxicity caused by cisplatin chemotherapy in patients one month to < 18 years of age with localised, non-metastatic, solid tumours. |
| Assessment Process | |
| Rapid review commissioned | 08/01/2025 |
| Rapid review completed | 06/02/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of sodium thiosulfate (Pedmarqsi®) compared with the current standard of care. |
